Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The company adds royalty aggregation to its R&D business.
And AbbVie and Genmab scoop their ASH presentation with new data.
But Enhertu is coming.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The restructured biotech’s new lead project enters phase 1.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
